{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,9]],"date-time":"2026-06-09T17:50:03Z","timestamp":1781027403022,"version":"3.54.1"},"reference-count":258,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2018,10,1]],"date-time":"2018-10-01T00:00:00Z","timestamp":1538352000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/100000027","name":"NIAAA","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000027","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003329","name":"Ministerio de Econom\u00eda y Competitividad","doi-asserted-by":"publisher","award":["PSI2014-51847-R"],"award-info":[{"award-number":["PSI2014-51847-R"]}],"id":[{"id":"10.13039\/501100003329","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003329","name":"Ministerio de Econom\u00eda y Competitividad","doi-asserted-by":"publisher","award":["2017-83023-R"],"award-info":[{"award-number":["2017-83023-R"]}],"id":[{"id":"10.13039\/501100003329","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004587","name":"Instituto de Salud Carlos III","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004587","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Red de Trastornos Adictivos","award":["RD12\/0028\/0005"],"award-info":[{"award-number":["RD12\/0028\/0005"]}]},{"name":"Uni\u00f3n Europea"},{"name":"Fondos FEDER \u201cuna manera de hacer Europa\u201d"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Pharmacology"],"published-print":{"date-parts":[[2018,10]]},"DOI":"10.1016\/j.ejphar.2018.08.007","type":"journal-article","created":{"date-parts":[[2018,8,7]],"date-time":"2018-08-07T16:52:39Z","timestamp":1533660759000},"page":"89-101","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":27,"special_numbering":"C","title":["Pharmacological treatments for opiate and alcohol addiction: A historical perspective of the last 50 years"],"prefix":"10.1016","volume":"836","author":[{"given":"M. Carmen","family":"Blanco-Gand\u00eda","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marta","family":"Rodr\u00edguez-Arias","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"9603","key":"10.1016\/j.ejphar.2018.08.007_bib1","doi-asserted-by":"crossref","first-page":"1915","DOI":"10.1016\/S0140-6736(07)61814-5","article-title":"Effectiveness and safety of baclofen for maintenance of alcohol abstinence in alcohol-dependent patients with liver cirrhosis: randomised, double-blind controlled study","volume":"370","author":"Addolorato","year":"2007","journal-title":"Lancet"},{"key":"10.1016\/j.ejphar.2018.08.007_bib2","unstructured":"Alcohol Fact Sheet, 2017 World Health Organization. \u3008www.euro.who.int\/alcohol\u3009."},{"key":"10.1016\/j.ejphar.2018.08.007_bib3","series-title":"Methadone Treatment Works: A Compendium for Methadone Maintenance Treatment","author":"Alcoholism","year":"1994"},{"issue":"1","key":"10.1016\/j.ejphar.2018.08.007_bib4","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1016\/S0376-8716(99)00074-5","article-title":"Efficacy of daily and alternate-day dosing regimens with the combination buprenorphine\u2013naloxone tablet","volume":"58","author":"Amass","year":"2000","journal-title":"Drug Alcohol Depend."},{"issue":"2","key":"10.1016\/j.ejphar.2018.08.007_bib5","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1016\/S0376-8716(00)00141-1","article-title":"Thrice-weekly supervised dosing with the combination buprenorphine-naloxone tablet is preferred to daily supervised dosing by opioid-dependent humans","volume":"61","author":"Amass","year":"2001","journal-title":"Drug Alcohol Depend."},{"issue":"4","key":"10.1016\/j.ejphar.2018.08.007_bib6","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1016\/j.jsat.2005.02.007","article-title":"An overview of systematic reviews of the effectiveness of opiate maintenance therapies: available evidence to inform clinical practice and research","volume":"28","author":"Amato","year":"2005","journal-title":"J. Subst. Abus. Treat."},{"key":"10.1016\/j.ejphar.2018.08.007_bib7","doi-asserted-by":"crossref","DOI":"10.1002\/14651858.CD003409.pub4","article-title":"Methadone at tapered doses for the management of opioid withdrawal","author":"Amato","year":"2013","journal-title":"Cochrane Database Syst. Rev."},{"issue":"2","key":"10.1016\/j.ejphar.2018.08.007_bib8","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1093\/alcalc\/agh130","article-title":"Complete and prolonged suppression of symptoms and consequences of alcohol-dependence using high-dose baclofen: a self-case report of a physician","volume":"40","author":"Ameisen","year":"2004","journal-title":"Alcohol Alcohol."},{"key":"10.1016\/j.ejphar.2018.08.007_bib9","unstructured":"ANSM, 2014. Recommandation Temporaire d\u2019Utilisation (RTU) du baclof\u00e8ne dans le traitement de l\u2019alcoolo-d\u00e9pendance."},{"key":"10.1016\/j.ejphar.2018.08.007_bib10","first-page":"11","article-title":"Pharmacologic approaches to the management of alcoholism","volume":"62","author":"Anton","year":"2001","journal-title":"J. Clin. Psychiatry"},{"issue":"4","key":"10.1016\/j.ejphar.2018.08.007_bib11","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1097\/01.jcp.0000130555.63254.73","article-title":"A multi-site dose ranging study of nalmefene in the treatment of alcohol dependence","volume":"24","author":"Anton","year":"2004","journal-title":"J. Clin. Psychopharmacol."},{"issue":"4","key":"10.1016\/j.ejphar.2018.08.007_bib12","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1097\/JCP.0b013e3181aba6a4","article-title":"Efficacy of a combination of flumazenil and gabapentin in the treatment of alcohol dependence: relationship to alcohol withdrawal symptoms","volume":"29","author":"Anton","year":"2009","journal-title":"J. Clin. Psychopharmacol."},{"issue":"7","key":"10.1016\/j.ejphar.2018.08.007_bib13","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1176\/appi.ajp.2011.10101436","article-title":"Gabapentin combined with naltrexone for the treatment of alcohol dependence","volume":"168","author":"Anton","year":"2011","journal-title":"Am. J. Psychiatry"},{"issue":"2","key":"10.1016\/j.ejphar.2018.08.007_bib14","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1080\/14740338.2018.1404025","article-title":"Alcohol addiction-the safety of available approved treatment options","volume":"17","author":"Antonelli","year":"2018","journal-title":"Expert Opin. Drug Saf."},{"issue":"S1","key":"10.1016\/j.ejphar.2018.08.007_bib15","doi-asserted-by":"crossref","DOI":"10.1080\/10550490490440780","article-title":"French field experience with buprenorphine","volume":"13","author":"Auriacombe","year":"2004","journal-title":"Am. J. Addict."},{"key":"10.1016\/j.ejphar.2018.08.007_bib16","series-title":"The Effectiveness of Methadone Maintenance Treatment: Patients, Programs, Services, and Outcome & Business Media","author":"Ball","year":"2012"},{"issue":"2","key":"10.1016\/j.ejphar.2018.08.007_bib17","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1097\/WNR.0b013e328363fde8","article-title":"Gabapentin attenuates morphine tolerance through interleukin-10","volume":"25","author":"Bao","year":"2014","journal-title":"Neuroreport"},{"issue":"3","key":"10.1016\/j.ejphar.2018.08.007_bib18","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1080\/10550887.2012.694598","article-title":"Maintenance medication for opiate addiction: the foundation of recovery","volume":"31","author":"Bart","year":"2012","journal-title":"J. Addict. Dis."},{"issue":"2","key":"10.1016\/j.ejphar.2018.08.007_bib19","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1016\/j.bcp.2013.10.028","article-title":"GHB receptor targets in the CNS: focus on high-affinity binding sites","volume":"87","author":"Bay","year":"2014","journal-title":"Biochem. Pharmacol."},{"issue":"1","key":"10.1016\/j.ejphar.2018.08.007_bib20","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1210\/jc.2004-0929","article-title":"Plasma testosterone and sexual function in men receiving buprenorphine maintenance for opioid dependence","volume":"90","author":"Bliesener","year":"2005","journal-title":"J. Clin. Endocrinol. Metab."},{"issue":"6","key":"10.1016\/j.ejphar.2018.08.007_bib21","doi-asserted-by":"crossref","first-page":"1481","DOI":"10.1111\/acer.12411","article-title":"A meta\u2010analysis of topiramate's effects for individuals with alcohol use disorders","volume":"38","author":"Blodgett","year":"2014","journal-title":"Alcohol.: Clin. Exp. Res."},{"key":"10.1016\/j.ejphar.2018.08.007_bib22","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1016\/S0027-9684(15)30175-9","article-title":"Opioid addiction and abuse in primary care practice: a comparison of methadone and buprenorphine as treatment options","volume":"104","author":"Bonhomme","year":"2012","journal-title":"J. Natl. Med. Assoc."},{"issue":"2","key":"10.1016\/j.ejphar.2018.08.007_bib23","doi-asserted-by":"crossref","first-page":"S5","DOI":"10.1016\/j.japh.2017.02.006","article-title":"Opioids, naloxone, and beyond: the intersection of medication safety, public health, and pharmacy","volume":"57","author":"Bratberg","year":"2017","journal-title":"J. Am. Pharm. Assoc."},{"issue":"6","key":"10.1016\/j.ejphar.2018.08.007_bib24","doi-asserted-by":"crossref","first-page":"722","DOI":"10.1038\/oby.2003.102","article-title":"A 6\u2010month randomized, placebo\u2010controlled, dose\u2010ranging trial of topiramate for weight loss in obesity","volume":"11","author":"Bray","year":"2003","journal-title":"Obesity"},{"issue":"8","key":"10.1016\/j.ejphar.2018.08.007_bib25","doi-asserted-by":"crossref","first-page":"1429","DOI":"10.1111\/j.1530-0277.2008.00706.x","article-title":"A randomized double\u2010blind pilot trial of gabapentin versus placebo to treat alcohol dependence and comorbid insomnia","volume":"32","author":"Brower","year":"2008","journal-title":"Alcohol.: Clin. Exp. Res."},{"issue":"2","key":"10.1016\/j.ejphar.2018.08.007_bib26","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1111\/j.1360-0443.2011.03637.x","article-title":"Engagement with opioid maintenance treatment and reductions in crime: a longitudinal national cohort study","volume":"107","author":"Bukten","year":"2012","journal-title":"Addiction"},{"issue":"4","key":"10.1016\/j.ejphar.2018.08.007_bib27","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1007\/s00210-003-0795-3","article-title":"Acamprosate blocks the increase in dopamine extracellular levels in nucleus accumbens evoked by chemical stimulation of the ventral hippocampus","volume":"368","author":"Cano-Cebrian","year":"2003","journal-title":"Naunyn-Schmiede.'s Arch. Pharmacol."},{"issue":"1","key":"10.1016\/j.ejphar.2018.08.007_bib28","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1016\/S0376-8716(02)00340-X","article-title":"Gamma-hydroxybutyric acid versus naltrexone in maintaining alcohol abstinence: an open randomized comparative study","volume":"70","author":"Caputo","year":"2003","journal-title":"Drug Alcohol Depend."},{"issue":"12","key":"10.1016\/j.ejphar.2018.08.007_bib29","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1016\/j.euroneuro.2007.04.008","article-title":"Comparing and combining gamma-hydroxybutyric acid (GHB) and naltrexone in maintaining abstinence from alcohol: an open randomised comparative study","volume":"17","author":"Caputo","year":"2007","journal-title":"Eur. Neuropsychopharmacol."},{"issue":"3","key":"10.1016\/j.ejphar.2018.08.007_bib30","doi-asserted-by":"crossref","first-page":"290","DOI":"10.3390\/ijerph13030290","article-title":"A brief up-date of the use of sodium oxybate for the treatment of alcohol use disorder","volume":"13","author":"Caputo","year":"2016","journal-title":"Int. J. Environ. Res. Public Health"},{"key":"10.1016\/j.ejphar.2018.08.007_bib31","unstructured":"CDC, 2015. Drug overdose deaths in the United States continue to increase. Centers for Disease Control and Prevention, Atlanta (GA); 2016. Available from: \u3008https:\/\/www.cdc.gov\/drugoverdose\/epidemic\/index.html\u3009."},{"key":"10.1016\/j.ejphar.2018.08.007_bib32","unstructured":"Center for Substance Abuse Treatment, 2009. Incorporating Alcohol Pharmacotherapies Into Medical Practice."},{"issue":"5","key":"10.1016\/j.ejphar.2018.08.007_bib33","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1016\/j.ajem.2014.01.015","article-title":"Prevalence and treatment of pain in EDs in the United States, 2000 to 2010","volume":"32","author":"Chang","year":"2014","journal-title":"Am. J. Emerg. Med."},{"issue":"5","key":"10.1016\/j.ejphar.2018.08.007_bib34","doi-asserted-by":"crossref","first-page":"1119","DOI":"10.1111\/adb.12414","article-title":"Harm reduction\u2014a systematic review on effects of alcohol reduction on physical and mental symptoms","volume":"22","author":"Charlet","year":"2017","journal-title":"Addict. Biol."},{"issue":"3","key":"10.1016\/j.ejphar.2018.08.007_bib35","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1007\/BF02254439","article-title":"Does gabapentin act as an agonist at native GABA B receptors?","volume":"11","author":"Cheng","year":"2004","journal-title":"J. Biomed. Sci."},{"issue":"3","key":"10.1016\/j.ejphar.2018.08.007_bib36","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1016\/S0924-9338(01)00562-4","article-title":"Long-term effects of topiramate on bipolar mood instability, weight change and glycemic control: a case-series","volume":"16","author":"Chengappa","year":"2001","journal-title":"Eur. Psychiatry"},{"issue":"2","key":"10.1016\/j.ejphar.2018.08.007_bib37","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1177\/0269881111408463","article-title":"Substitution therapy for alcoholism: time for a reappraisal?","volume":"26","author":"Chick","year":"2012","journal-title":"J. Psychopharmacol."},{"issue":"4","key":"10.1016\/j.ejphar.2018.08.007_bib38","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1016\/S0361-9230(98)00016-1","article-title":"Central 5-HT3 receptors in P and in AA alcohol-preferring rats: an autoradiographic study","volume":"46","author":"Ciccocioppo","year":"1998","journal-title":"Brain Res. Bull."},{"issue":"7","key":"10.1016\/j.ejphar.2018.08.007_bib39","doi-asserted-by":"crossref","first-page":"821","DOI":"10.1001\/jamapsychiatry.2014.366","article-title":"The changing face of heroin use in the United States: a retrospective analysis of the past 50 years","volume":"71","author":"Cicero","year":"2014","journal-title":"JAMA Psychiatry"},{"issue":"10","key":"10.1016\/j.ejphar.2018.08.007_bib40","doi-asserted-by":"crossref","first-page":"3474","DOI":"10.1021\/jm050069n","article-title":"Varenicline: an alpha4beta2 nicotinic receptor partial agonist for smoking cessation","volume":"48","author":"Coe","year":"2005","journal-title":"J. Med. Chem."},{"issue":"4","key":"10.1016\/j.ejphar.2018.08.007_bib41","doi-asserted-by":"crossref","first-page":"664","DOI":"10.1007\/s00213-005-0023-6","article-title":"Buprenorphine\/naloxone reduces the reinforcing and subjective effects of heroin in heroin-dependent volunteers","volume":"181","author":"Comer","year":"2005","journal-title":"Psychopharmacology"},{"issue":"3","key":"10.1016\/j.ejphar.2018.08.007_bib42","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1007\/s00213-006-0571-4","article-title":"Effects associated with double-blind omission of buprenorphine\/naloxone over a 98-h period","volume":"189","author":"Correia","year":"2006","journal-title":"Psychopharmacology"},{"key":"10.1016\/j.ejphar.2018.08.007_bib43","series-title":"Dark Paradise: Opioid Addiction in America Before 1940","author":"Courtwright","year":"1982"},{"issue":"2","key":"10.1016\/j.ejphar.2018.08.007_bib44","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/j.euroneuro.2009.11.001","article-title":"The nicotinic acetylcholine receptor partial agonist varenicline and the treatment of drug dependence: a review","volume":"20","author":"Crunelle","year":"2010","journal-title":"Eur. Neuropsychopharmacol."},{"issue":"1","key":"10.1016\/j.ejphar.2018.08.007_bib45","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1038\/clpt.1992.106","article-title":"Treatment of opioid\u2010induced constipation with oral naloxone: a pilot study","volume":"52","author":"Culpepper\u2010Morgan","year":"1992","journal-title":"Clin. Pharmacol. Ther."},{"issue":"6","key":"10.1016\/j.ejphar.2018.08.007_bib46","doi-asserted-by":"crossref","first-page":"1566","DOI":"10.1111\/j.1460-9568.2004.03625.x","article-title":"Dual effects of gabapentin and pregabalin on glutamate release at rat entorhinal synapses in vitro","volume":"20","author":"Cunningham","year":"2004","journal-title":"Eur. J. Neurosci."},{"issue":"1","key":"10.1016\/j.ejphar.2018.08.007_bib47","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1016\/0002-9343(78)90691-5","article-title":"Abstinence following detoxification and methadone maintenance treatment","volume":"65","author":"Cushman","year":"1978","journal-title":"Am. J. Med."},{"issue":"3","key":"10.1016\/j.ejphar.2018.08.007_bib48","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1016\/0741-8329(87)90037-1","article-title":"Selected opioids modify intake of sweetened ethanol solution among female rats","volume":"4","author":"Czirr","year":"1987","journal-title":"Alcohol"},{"issue":"6","key":"10.1016\/j.ejphar.2018.08.007_bib49","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1093\/bja\/aei145","article-title":"Comparison of the respiratory effects of intravenous buprenorphine and fentanyl in humans and rats","volume":"94","author":"Dahan","year":"2005","journal-title":"Br. J. Anaesth."},{"issue":"2","key":"10.1016\/j.ejphar.2018.08.007_bib50","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1016\/S0925-4927(98)00016-X","article-title":"Central effects of acamprosate: Part 1. Acamprosate blocks the glutamate increase in the nucleus accumbens microdialysate in ethanol withdrawn rats","volume":"82","author":"Dahchour","year":"1998","journal-title":"Psychiatry Res.: Neuroimaging"},{"issue":"1","key":"10.1016\/j.ejphar.2018.08.007_bib51","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1111\/j.1749-6632.1978.tb16775.x","article-title":"Long\u2010term outcome of patients treated with methadone maintenance","volume":"311","author":"Dole","year":"1978","journal-title":"Ann. N.Y. Acad. Sci."},{"issue":"8","key":"10.1016\/j.ejphar.2018.08.007_bib52","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1001\/jama.1965.03090080008002","article-title":"A medical treatment for diacetylmorphine (heroin) addiction: a clinical trial with methadone hydrochloride","volume":"193","author":"Dole","year":"1965","journal-title":"Jama"},{"issue":"4","key":"10.1016\/j.ejphar.2018.08.007_bib53","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1001\/archinte.1966.00290160004002","article-title":"Narcotic blockade","volume":"118","author":"Dole","year":"1966","journal-title":"Arch. Intern. Med."},{"issue":"6","key":"10.1016\/j.ejphar.2018.08.007_bib54","doi-asserted-by":"crossref","first-page":"920","DOI":"10.1111\/add.12875","article-title":"The efficacy of acamprosate and naltrexone in the treatment of alcohol dependence, Europe versus the rest of the world: a meta\u2010analysis","volume":"110","author":"Donoghue","year":"2015","journal-title":"Addiction"},{"issue":"2","key":"10.1016\/j.ejphar.2018.08.007_bib55","doi-asserted-by":"crossref","first-page":"80","DOI":"10.3109\/00952990.2013.764885","article-title":"Pharmacokinetic interactions between buprenorphine\/naloxone and raltegravir in subjects receiving chronic buprenorphine\/naloxone treatment","volume":"39","author":"Douglas Bruce","year":"2013","journal-title":"Am. J. Drug Alcohol Abus."},{"issue":"8","key":"10.1016\/j.ejphar.2018.08.007_bib56","doi-asserted-by":"crossref","first-page":"1101","DOI":"10.1111\/j.1360-0443.2005.001128.x","article-title":"Comparative study of the effectiveness of slow\u2010release morphine and methadone for opioid maintenance therapy","volume":"100","author":"Eder","year":"2005","journal-title":"Addiction"},{"issue":"11","key":"10.1016\/j.ejphar.2018.08.007_bib57","doi-asserted-by":"crossref","first-page":"1445","DOI":"10.1177\/1060028014545806","article-title":"Varenicline in the treatment of alcohol use disorders","volume":"48","author":"Erwin","year":"2014","journal-title":"Ann. Pharmacother."},{"issue":"15","key":"10.1016\/j.ejphar.2018.08.007_bib58","doi-asserted-by":"crossref","first-page":"1553","DOI":"10.1001\/archinte.166.15.1553","article-title":"Cytisine for smoking cessation: a literature review and a meta-analysis","volume":"166","author":"Etter","year":"2006","journal-title":"Arch. Intern. Med."},{"key":"10.1016\/j.ejphar.2018.08.007_bib59","volume":"2017","author":"European Drug Report","year":"2017"},{"key":"10.1016\/j.ejphar.2018.08.007_bib60","unstructured":"European Medicines Agency. Subuxone. Available at: \u3008http:\/\/www.ema.europa.eu\/ema\/index.jsp?CurlDpages\/medicines\/human\/medicines\/000697\/human_med_001067.jsp&midDWC0b01ac058001d124\u3009."},{"key":"10.1016\/j.ejphar.2018.08.007_bib61","unstructured":"European Medicines Agency, 2013. Subuxone. Available at: \u3008http:\/\/www.ema.europa.eu\/ema\/index.jsp?CurlDpages\/medicines\/human\/medi-cines\/000697\/human_med_001067.jsp&midDWC0b01ac058001d124\u3009. (Accessed 18 September)."},{"key":"10.1016\/j.ejphar.2018.08.007_bib62","unstructured":"European Medicines Agency, 2018EPAR Summary for the Public. Champix Varenicline. London. (Last updated 21\/02\/2018, Retrieved 20-04-2018)."},{"issue":"1","key":"10.1016\/j.ejphar.2018.08.007_bib63","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1002\/syn.10238","article-title":"Baclofen antagonizes nicotine\u2010, cocaine\u2010, and morphine\u2010induced dopamine release in the nucleus accumbens of rat","volume":"50","author":"Fadda","year":"2003","journal-title":"Synapse"},{"issue":"4","key":"10.1016\/j.ejphar.2018.08.007_bib64","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1097\/ADM.0000000000000133","article-title":"Moderators of varenicline treatment effects in a double-blind, placebo-controlled trial for alcohol dependence: an exploratory analysis","volume":"9","author":"Falk","year":"2015","journal-title":"J. Addict. Med."},{"key":"10.1016\/j.ejphar.2018.08.007_bib65","unstructured":"FDA, 2002. Approval Letter for Xyrem; Indication: Cataplexy associated with narcolepsy. US Food and Drug Administration-07-17."},{"key":"10.1016\/j.ejphar.2018.08.007_bib66","unstructured":"Fishman, J., 1974. U.S. Patent No. 3,814,768. Washington, DC: U.S. Patent and Trademark Office."},{"issue":"8","key":"10.1016\/j.ejphar.2018.08.007_bib67","doi-asserted-by":"crossref","first-page":"1477","DOI":"10.1111\/add.13438","article-title":"Weak evidence on nalmefene creates dilemmas for clinicians and poses questions for regulators and researchers","volume":"111","author":"Fitzgerald","year":"2016","journal-title":"Addiction"},{"issue":"10053","key":"10.1016\/j.ejphar.2018.08.007_bib68","doi-asserted-by":"crossref","first-page":"1659","DOI":"10.1016\/S0140-6736(16)31679-8","article-title":"Global, regional, and national comparative risk assessment of 79 behavioural, environmental and occupational, and metabolic risks or clusters of risks, 1990\u20132015: a systematic analysis for the Global Burden of Disease Study 2015","volume":"388","author":"Forouzanfar","year":"2016","journal-title":"Lancet"},{"issue":"4","key":"10.1016\/j.ejphar.2018.08.007_bib69","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1007\/s00213-010-2160-9","article-title":"A preliminary investigation of varenicline for heavy drinking smokers","volume":"215","author":"Fucito","year":"2011","journal-title":"Psychopharmacology"},{"issue":"1","key":"10.1016\/j.ejphar.2018.08.007_bib70","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1111\/j.1360-0443.2004.00597.x","article-title":"Does disulfiram have a role in alcoholism treatment today?","volume":"99","author":"Fuller","year":"2004","journal-title":"Addiction"},{"issue":"11","key":"10.1016\/j.ejphar.2018.08.007_bib71","doi-asserted-by":"crossref","first-page":"1691","DOI":"10.4088\/JCP.v68n1108","article-title":"Gabapentin reduces alcohol consumption and craving: a randomized, double-blind, placebo-controlled trial","volume":"68","author":"Furieri","year":"2007","journal-title":"J. Clin. Psychiatry"},{"issue":"4","key":"10.1016\/j.ejphar.2018.08.007_bib72","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1111\/j.1530-0277.1992.tb00658.x","article-title":"Gamma\u2010hydroxybutyric acid in the treatment of alcohol dependence: a double\u2010blind study","volume":"16","author":"Gallimberti","year":"1992","journal-title":"Alcohol.: Clin. Exp. Res."},{"issue":"13","key":"10.1016\/j.ejphar.2018.08.007_bib73","doi-asserted-by":"crossref","first-page":"1617","DOI":"10.1001\/jama.293.13.1617","article-title":"Efficacy and tolerability of long-acting injectable naltrexone for alcohol dependence: a randomized controlled trial","volume":"293","author":"Garbutt","year":"2005","journal-title":"JAMA"},{"issue":"11","key":"10.1016\/j.ejphar.2018.08.007_bib74","doi-asserted-by":"crossref","first-page":"1849","DOI":"10.1111\/j.1530-0277.2010.01273.x","article-title":"Efficacy and safety of baclofen for alcohol dependence: a randomized, double\u2010blind, placebo\u2010controlled trial","volume":"34","author":"Garbutt","year":"2010","journal-title":"Alcohol.: Clin. Exp. Res."},{"issue":"7","key":"10.1016\/j.ejphar.2018.08.007_bib75","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1111\/apt.13965","article-title":"Pharmacotherapy for alcohol dependence\u2013the why, the what and the wherefore","volume":"45","author":"Goh","year":"2017","journal-title":"Aliment. Pharmacol. Ther."},{"issue":"6","key":"10.1016\/j.ejphar.2018.08.007_bib76","doi-asserted-by":"crossref","DOI":"10.1097\/00000542-199912000-00015","article-title":"Rapid opioid detoxification during general anesthesia a review of 20 patients","volume":"91","author":"Gold","year":"1999","journal-title":"Anesthesiol.: J. Am. Soc. Anesthesiol."},{"issue":"5","key":"10.1016\/j.ejphar.2018.08.007_bib77","doi-asserted-by":"crossref","first-page":"566","DOI":"10.1016\/S0196-0644(86)80994-5","article-title":"A dosing nomogram for continuous infusion intravenous naloxone","volume":"15","author":"Goldfrank","year":"1986","journal-title":"Ann. Emerg. Med."},{"issue":"9","key":"10.1016\/j.ejphar.2018.08.007_bib78","doi-asserted-by":"crossref","first-page":"1331","DOI":"10.2165\/00003495-200262090-00004","article-title":"Treatment of heroin (diamorphine) addiction","volume":"62","author":"Gonzalez","year":"2002","journal-title":"Drugs"},{"issue":"3","key":"10.1016\/j.ejphar.2018.08.007_bib79","doi-asserted-by":"crossref","first-page":"192","DOI":"10.2165\/00003495-198835030-00002","article-title":"Naltrexone","volume":"35","author":"Gonzalez","year":"1988","journal-title":"Drugs"},{"issue":"4","key":"10.1016\/j.ejphar.2018.08.007_bib80","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1300\/J069v12n04_04","article-title":"Diminished illicit drug use as a consequence of long-term methadone maintenance","volume":"12","author":"Gottheil","year":"1993","journal-title":"J. Addict. Dis."},{"key":"10.1016\/j.ejphar.2018.08.007_bib81","article-title":"Opioid antagonists under heavy sedation or anaesthesia for opioid withdrawal","volume":"2","author":"Gowing","year":"2006","journal-title":"Cochrane Database Syst. Rev."},{"issue":"11","key":"10.1016\/j.ejphar.2018.08.007_bib82","doi-asserted-by":"crossref","first-page":"2000","DOI":"10.1038\/sj.npp.1300251","article-title":"Effects of buprenorphine maintenance dose on \u03bc-opioid receptor availability, plasma concentrations, and antagonist blockade in heroin-dependent volunteers","volume":"28","author":"Greenwald","year":"2003","journal-title":"Neuropsychopharmacology"},{"issue":"3","key":"10.1016\/j.ejphar.2018.08.007_bib83","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1111\/j.1600-0447.1990.tb03057.x","article-title":"Mortality in heroin addiction: impact of methadone treatment","volume":"82","author":"Gr\u00f6nbladh","year":"1990","journal-title":"Acta Psychiatr. Scand."},{"issue":"3","key":"10.1016\/j.ejphar.2018.08.007_bib84","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1093\/cid\/cir799","article-title":"Interactions between buprenorphine and the protease inhibitors darunavir-ritonavir and fosamprenavir-ritonavir","volume":"54","author":"Gruber","year":"2011","journal-title":"Clin. Infect. Dis."},{"issue":"11","key":"10.1016\/j.ejphar.2018.08.007_bib85","doi-asserted-by":"crossref","first-page":"1432","DOI":"10.1016\/j.euroneuro.2013.02.006","article-title":"A randomised, double-blind, placebo-controlled, efficacy study of nalmefene, as-needed use, in patients with alcohol dependence","volume":"23","author":"Gual","year":"2013","journal-title":"Eur. Neuropsychopharmacol."},{"issue":"12","key":"10.1016\/j.ejphar.2018.08.007_bib86","doi-asserted-by":"crossref","first-page":"833","DOI":"10.1111\/j.2042-7158.1983.tb02910.x","article-title":"Naloxone radioimmunoassay: an improved antiserum","volume":"35","author":"Hahn","year":"1983","journal-title":"J. Pharm. Pharmacol."},{"issue":"3\u20104","key":"10.1016\/j.ejphar.2018.08.007_bib87","first-page":"305","article-title":"The formation of acetaldehyde in the organism after ingestion of antabuse (Tetraethylthiuramdisulphide) and alcohol","volume":"4","author":"Hald","year":"1948","journal-title":"Basic Clin. Pharmacol. Toxicol."},{"issue":"3","key":"10.1016\/j.ejphar.2018.08.007_bib88","doi-asserted-by":"crossref","first-page":"684","DOI":"10.1111\/j.1743-6109.2007.00702.x","article-title":"Erectile dysfunction in men receiving methadone and buprenorphine maintenance treatment","volume":"5","author":"Hallinan","year":"2008","journal-title":"J. Sex. Med."},{"issue":"11","key":"10.1016\/j.ejphar.2018.08.007_bib89","doi-asserted-by":"crossref","first-page":"1724","DOI":"10.1097\/01.ALC.0000093601.33119.E3","article-title":"The neurotoxicity induced by ethanol withdrawal in mature organotypic hippocampal slices might involve cross\u2010talk between metabotropic glutamate type 5 receptors and N\u2010Methyl\u2010d\u2010Aspartate receptors","volume":"27","author":"Harris","year":"2003","journal-title":"Alcohol.: Clin. Exp. Res."},{"issue":"2","key":"10.1016\/j.ejphar.2018.08.007_bib90","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1016\/j.pbb.2003.11.015","article-title":"Reduced 5-HT3 receptor binding and lower baseline plus maze anxiety in the alcohol-preferring inbred fawn-hooded rat","volume":"77","author":"Hensler","year":"2004","journal-title":"Pharmacol. Biochem. Behav."},{"issue":"10","key":"10.1016\/j.ejphar.2018.08.007_bib91","doi-asserted-by":"crossref","first-page":"1807","DOI":"10.1038\/sj.npp.1300498","article-title":"5-HT 3A receptor subunit is required for 5-HT 3 antagonist-induced reductions in alcohol drinking","volume":"29","author":"Hodge","year":"2004","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.ejphar.2018.08.007_bib92","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/j.addbeh.2014.11.007","article-title":"Varenicline for opioid withdrawal in patients with chronic pain: a randomized, single-blinded, placebo controlled pilot trial","volume":"42","author":"Hooten","year":"2015","journal-title":"Addict. Behav."},{"issue":"1","key":"10.1016\/j.ejphar.2018.08.007_bib93","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/0741-8329(86)90070-4","article-title":"Consumption of ethanol solution is potentiated by morphine and attenuated by naloxone persistently across repeated daily administrations","volume":"3","author":"Hubbell","year":"1986","journal-title":"Alcohol"},{"issue":"10","key":"10.1016\/j.ejphar.2018.08.007_bib94","doi-asserted-by":"crossref","first-page":"1108","DOI":"10.1001\/archgenpsychiatry.2009.130","article-title":"Improving clinical outcomes in treating heroin dependence: randomized, controlled trial of oral or implant naltrexone","volume":"66","author":"Hulse","year":"2009","journal-title":"Arch. Gen. Psychiatry"},{"key":"10.1016\/j.ejphar.2018.08.007_bib95","unstructured":"International Narcotics Control Board, 2015. Availability of Internationally Controlled Drugs. Vienna (Austria): International Narcotics Control Board [3294147]. Available from: \u3008http:\/\/www.incb.org\/documents\/Publications\/AnnualReports\/AR2015\/English\/Supp\/AR15_Availability_E_Chapter_II_B.pdf\u3009."},{"issue":"3","key":"10.1016\/j.ejphar.2018.08.007_bib96","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/S0002-9343(84)80100-X","article-title":"Role of opioid analgesics","volume":"77","author":"Inturrisi","year":"1984","journal-title":"Am. J. Med."},{"issue":"5part1","key":"10.1016\/j.ejphar.2018.08.007_bib97","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1002\/cpt1972135part1633","article-title":"The levels of methadone in the plasma in methadone maintenance","volume":"13","author":"Inturrisi","year":"1972","journal-title":"Clin. Pharmacol. Ther."},{"issue":"6","key":"10.1016\/j.ejphar.2018.08.007_bib98","doi-asserted-by":"crossref","first-page":"923","DOI":"10.1002\/cpt1972136923","article-title":"Disposition of methadone in man after a single oral dose","volume":"13","author":"Inturrisi","year":"1972","journal-title":"Clin. Pharmacol. Ther."},{"issue":"2","key":"10.1016\/j.ejphar.2018.08.007_bib99","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1016\/S0021-9673(00)92558-5","article-title":"A gas-liquid chromatographic method for the quantitative determination of methadone in human plasma and urine","volume":"65","author":"Inturrisi","year":"1972","journal-title":"J. Chromatogr. A"},{"key":"10.1016\/j.ejphar.2018.08.007_bib100","series-title":"The Pharmacologic Basis of Therapeutics","first-page":"491","article-title":"Opioid analgesics and antagonists","author":"Jaffe","year":"1980"},{"issue":"4","key":"10.1016\/j.ejphar.2018.08.007_bib101","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1111\/j.1360-0443.2006.01369.x","article-title":"Efficacy of maintenance treatment with naltrexone for opioid dependence: a meta\u2010analytical review","volume":"101","author":"Johansson","year":"2006","journal-title":"Addiction"},{"issue":"4","key":"10.1016\/j.ejphar.2018.08.007_bib102","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1007\/s002130000371","article-title":"Neuropharmacological treatments for alcoholism: scientific basis and clinical findings","volume":"149","author":"Johnson","year":"2000","journal-title":"Psychopharmacology"},{"issue":"9370","key":"10.1016\/j.ejphar.2018.08.007_bib103","doi-asserted-by":"crossref","first-page":"1677","DOI":"10.1016\/S0140-6736(03)13370-3","article-title":"Oral topiramate for treatment of alcohol dependence: a randomised controlled trial","volume":"361","author":"Johnson","year":"2003","journal-title":"Lancet"},{"issue":"9","key":"10.1016\/j.ejphar.2018.08.007_bib104","doi-asserted-by":"crossref","first-page":"905","DOI":"10.1001\/archpsyc.61.9.905","article-title":"Oral topiramate reduces the consequences of drinking and improves the quality of life of alcohol-dependent individuals: a randomized controlled trial","volume":"61","author":"Johnson","year":"2004","journal-title":"Arch. Gen. Psychiatry"},{"issue":"14","key":"10.1016\/j.ejphar.2018.08.007_bib105","doi-asserted-by":"crossref","first-page":"1641","DOI":"10.1001\/jama.298.14.1641","article-title":"Topiramate for treating alcohol dependence: a randomized controlled trial","volume":"298","author":"Johnson","year":"2007","journal-title":"Jama"},{"issue":"3","key":"10.1016\/j.ejphar.2018.08.007_bib106","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1176\/appi.ajp.2010.10050755","article-title":"Pharmacogenetic approach at the serotonin transporter gene as a method of reducing the severity of alcohol drinking","volume":"168","author":"Johnson","year":"2011","journal-title":"Am. J. Psychiatry"},{"issue":"18","key":"10.1016\/j.ejphar.2018.08.007_bib107","doi-asserted-by":"crossref","first-page":"1889","DOI":"10.1001\/jama.2014.3628","article-title":"Pharmacotherapy for adults with alcohol use disorders in outpatient settings: a systematic review and meta-analysis","volume":"311","author":"Jonas","year":"2014","journal-title":"Jama"},{"key":"10.1016\/j.ejphar.2018.08.007_bib108","series-title":"cd. State Methadone Treatment Guidelines","article-title":"Historical perspectives and public health issues","author":"Joseph","year":"1991"},{"issue":"9","key":"10.1016\/j.ejphar.2018.08.007_bib109","doi-asserted-by":"crossref","first-page":"1333","DOI":"10.1111\/j.1360-0443.2006.01512.x","article-title":"Methadone\u2010associated Torsades de Pointes (polymorphic ventricular tachycardia) in opioid\u2010dependent patients","volume":"101","author":"Justo","year":"2006","journal-title":"Addiction"},{"issue":"2","key":"10.1016\/j.ejphar.2018.08.007_bib110","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1016\/S0021-9673(01)91836-9","article-title":"A gas\u2014liquid chromatographic method for the quantitative determination of acetylmethadol and its metabolites in human urine","volume":"82","author":"Kaiko","year":"1973","journal-title":"J. Chromatogr. A"},{"issue":"1","key":"10.1016\/j.ejphar.2018.08.007_bib111","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1002\/cpt197518196","article-title":"Disposition of acetylmethadol in relation to pharmacologic action","volume":"18","author":"Kaiko","year":"1975","journal-title":"Clin. Pharmacol. Ther."},{"issue":"9358","key":"10.1016\/j.ejphar.2018.08.007_bib112","doi-asserted-by":"crossref","first-page":"662","DOI":"10.1016\/S0140-6736(03)12600-1","article-title":"1-year retention and social function after buprenorphine-assisted relapse prevention treatment for heroin dependence in Sweden: a randomised, placebo-controlled trial","volume":"361","author":"Kakko","year":"2003","journal-title":"Lancet"},{"issue":"7","key":"10.1016\/j.ejphar.2018.08.007_bib113","doi-asserted-by":"crossref","first-page":"1179","DOI":"10.1111\/j.1530-0277.2007.00401.x","article-title":"Targeted nalmefene with simple medical management in the treatment of heavy drinkers: a randomized double\u2010blind placebo\u2010controlled multicenter study","volume":"31","author":"Karhuvaara","year":"2007","journal-title":"Alcohol.: Clin. Exp. Res."},{"issue":"11","key":"10.1016\/j.ejphar.2018.08.007_bib114","doi-asserted-by":"crossref","first-page":"1837","DOI":"10.1111\/j.1360-0443.2008.02334.x","article-title":"Slow\u2010release oral morphine for maintenance treatment of opioid addicts intolerant to methadone or with inadequate withdrawal suppression","volume":"103","author":"Kastelic","year":"2008","journal-title":"Addiction"},{"issue":"2","key":"10.1016\/j.ejphar.2018.08.007_bib115","doi-asserted-by":"crossref","first-page":"688","DOI":"10.1124\/jpet.102.038240","article-title":"Influence of opioid agonists on cardiac humanether-a-go-go-related gene K+ currents","volume":"303","author":"Katchman","year":"2002","journal-title":"J. Pharmacol. Exp. Ther."},{"issue":"4","key":"10.1016\/j.ejphar.2018.08.007_bib116","doi-asserted-by":"crossref","first-page":"838","DOI":"10.1111\/acer.12996","article-title":"Single\u2010dose interaction study of the arginine vasopressin type 1B receptor antagonist ABT\u2010436 and alcohol in moderate alcohol drinkers","volume":"40","author":"Katz","year":"2016","journal-title":"Alcohol.: Clin. Exp. Res."},{"issue":"9","key":"10.1016\/j.ejphar.2018.08.007_bib117","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1007\/s40263-013-0101-y","article-title":"Nalmefene: a review of its use in the treatment of alcohol dependence","volume":"27","author":"Keating","year":"2013","journal-title":"CNS Drugs"},{"issue":"19","key":"10.1016\/j.ejphar.2018.08.007_bib118","doi-asserted-by":"crossref","first-page":"2303","DOI":"10.1001\/jama.2008.648","article-title":"Methadone maintenance 4 decades later: thousands of lives saved but still controversial","volume":"300","author":"Kleber","year":"2008","journal-title":"JAMA"},{"key":"10.1016\/j.ejphar.2018.08.007_bib119","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1146\/annurev.psych.59.103006.093548","article-title":"Addiction and the brain antireward system","volume":"59","author":"Koob","year":"2008","journal-title":"Annu. Rev. Psychol."},{"issue":"6","key":"10.1016\/j.ejphar.2018.08.007_bib120","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1016\/0024-3205(88)90454-7","article-title":"Buprenorphine detoxification from opiod dependence: a pilot study","volume":"42","author":"Kosten","year":"1988","journal-title":"Life Sci."},{"issue":"1","key":"10.1016\/j.ejphar.2018.08.007_bib121","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/0024-3205(86)90437-6","article-title":"A preliminary study of beta endorphin during chronic naltrexone maintenance treatment in ex-opiate addicts","volume":"39","author":"Kosten","year":"1986","journal-title":"Life Sci."},{"issue":"2","key":"10.1016\/j.ejphar.2018.08.007_bib122","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1016\/0006-3223(86)90150-2","article-title":"Cortisol levels during chronic naltrexone maintenance treatment in ex-opiate addicts","volume":"21","author":"Kosten","year":"1986","journal-title":"Biol. Psychiatry"},{"issue":"9","key":"10.1016\/j.ejphar.2018.08.007_bib123","doi-asserted-by":"crossref","first-page":"1071","DOI":"10.1016\/0024-3205(87)90623-0","article-title":"Beta endorphin levels in CSF during methadone maintenance","volume":"41","author":"Kosten","year":"1987","journal-title":"Life Sci."},{"issue":"6","key":"10.1016\/j.ejphar.2018.08.007_bib124","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1016\/0006-3223(92)90220-T","article-title":"Beta endorphin levels during heroin, methadone, buprenorphine, and naloxone challenges: preliminary findings","volume":"32","author":"Kosten","year":"1992","journal-title":"Biol. Psychiatry"},{"issue":"3","key":"10.1016\/j.ejphar.2018.08.007_bib125","first-page":"133","article-title":"Studies on the effects of certain 5-HT-3 receptor antagonists on ethanol preference and withdrawal seizures in the rat","volume":"46","author":"Kostowski","year":"1994","journal-title":"Pol. J. Pharmacol."},{"issue":"3","key":"10.1016\/j.ejphar.2018.08.007_bib126","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1159\/000085550","article-title":"Use of slow-release oral morphine for the treatment of opioid dependence","volume":"11","author":"Kraigher","year":"2008","journal-title":"Eur. Addict. Res."},{"issue":"7","key":"10.1016\/j.ejphar.2018.08.007_bib127","doi-asserted-by":"crossref","first-page":"1150","DOI":"10.1097\/01.ALC.0000075547.77464.76","article-title":"Effects of ondansetron in early\u2010versus late\u2010onset alcoholics: a prospective, open\u2010label study","volume":"27","author":"Kranzler","year":"2003","journal-title":"Alcohol.: Clin. Exp. Res."},{"issue":"2","key":"10.1016\/j.ejphar.2018.08.007_bib128","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1111\/adb.12207","article-title":"Self\u2010efficacy mediates the effects of topiramate and GRIK1 genotype on drinking","volume":"21","author":"Kranzler","year":"2016","journal-title":"Addict. Biol."},{"issue":"4","key":"10.1016\/j.ejphar.2018.08.007_bib129","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1097\/ADM.0b013e3182312983","article-title":"Statement of the American Society of Addiction Medicine Consensus Panel on the use of buprenorphine in office-based treatment of opioid addiction","volume":"5","author":"Kraus","year":"2011","journal-title":"J. Addict. Med."},{"key":"10.1016\/j.ejphar.2018.08.007_bib130","first-page":"205","article-title":"Rationale for maintenance pharmacotherapy of opiate dependence","volume":"70","author":"Kreek","year":"1992","journal-title":"Res. Publ.-Assoc. Res. Nerv. Ment. Dis."},{"key":"10.1016\/j.ejphar.2018.08.007_bib131","doi-asserted-by":"crossref","unstructured":"Kreek, M.J., 1972. Medical safety, side effects and toxicity of methadone. In: Proceedings of the Fourth National Conference on Methadone Treatment, NAPAN-NIMH pp. 171\u2013174. \u3008http:\/\/dx.doi.org\/10.1001\/jama.223.6.665\u3009.","DOI":"10.1001\/jama.223.6.665"},{"issue":"6","key":"10.1016\/j.ejphar.2018.08.007_bib132","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1001\/jama.1973.03220060039009","article-title":"Medical safety and side effects of methadone in tolerant individuals","volume":"223","author":"Kreek","year":"1973","journal-title":"Jama"},{"issue":"1","key":"10.1016\/j.ejphar.2018.08.007_bib133","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1111\/j.1749-6632.1978.tb16769.x","article-title":"Medical complications in methadone patients","volume":"311","author":"Kreek","year":"1978","journal-title":"Ann. N.Y. Acad. Sci."},{"key":"10.1016\/j.ejphar.2018.08.007_bib134","first-page":"7","article-title":"Methadone disposition during the perinatal period in humans","volume":"11","author":"Kreek","year":"1979","journal-title":"Pharmacol. Biochem. Behav."},{"issue":"362","key":"10.1016\/j.ejphar.2018.08.007_bib135","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1111\/j.1749-6632.1981.tb12789.x","article-title":"Metabolic interactions between opiates and alcohol","volume":"1981","author":"Kreek","year":"1981","journal-title":"Ann. N.Y. Acad. Sci."},{"issue":"4","key":"10.1016\/j.ejphar.2018.08.007_bib136","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1300\/J251v03n04_04","article-title":"Opioid interactions with alcohol","volume":"3","author":"Kreek","year":"1984","journal-title":"Adv. Alcohol Subst. Abus."},{"issue":"1","key":"10.1016\/j.ejphar.2018.08.007_bib137","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1111\/j.1749-6632.2000.tb06683.x","article-title":"Methadone\u2010related opioid agonist pharmacotherapy for heroin addiction: history, recent molecular and neurochemical research and future in mainstream medicine","volume":"909","author":"Kreek","year":"2000","journal-title":"Ann. N.Y. Acad. Sci."},{"issue":"3","key":"10.1016\/j.ejphar.2018.08.007_bib138","doi-asserted-by":"crossref","first-page":"409","DOI":"10.3109\/00952997409011033","article-title":"Analyses of methadone and other drugs in maternal and neonatal body fluids: use in evaluation of symptoms in a neonate of mother maintained on methadone","volume":"1","author":"Kreek","year":"1974","journal-title":"Am. J. Drug Alcohol Abus."},{"issue":"20","key":"10.1016\/j.ejphar.2018.08.007_bib139","doi-asserted-by":"crossref","first-page":"1104","DOI":"10.1056\/NEJM197605132942008","article-title":"Rifampin-induced methadone withdrawal","volume":"294","author":"Kreek","year":"1976","journal-title":"New Engl. J. Med."},{"issue":"8319","key":"10.1016\/j.ejphar.2018.08.007_bib140","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1016\/S0140-6736(83)91684-7","article-title":"Naloxone, a specific opioid antagonist, reverses chronic idiopathic constipation","volume":"321","author":"Kreek","year":"1983","journal-title":"Lancet"},{"key":"10.1016\/j.ejphar.2018.08.007_bib141","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1016\/j.neuropharm.2004.07.024","article-title":"Evolving perspectives on neurobiological research on the addictions: celebration of the 30th anniversary of NIDA","volume":"47","author":"Kreek","year":"2004","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.ejphar.2018.08.007_bib142","doi-asserted-by":"crossref","unstructured":"Kreek, M.J., 1991a. Using methadone effectively: Achieving goals by application of laboratory, clinical, and evaluation research and by development of innovative programs. Pickens, R.; Leukefeld, C.; and Schuster, CR, pp. 245\u2013266. \u3008https:\/\/doi.org\/10.1037\/e496292006-013\u3009.","DOI":"10.1037\/e496292006-013"},{"key":"10.1016\/j.ejphar.2018.08.007_bib143","doi-asserted-by":"crossref","unstructured":"Kreek, M.J., 1996. Long-term pharmacotherapy for opiate (primarily heroin) addiction: opioid agonists. In: Pharmacological Aspects of Drug Dependence. Springer, Berlin, Heidelberg, pp. 487\u2013562. \u3008https:\/\/doi.org\/10.1007\/978-3-642-60963-3_14\u3009.","DOI":"10.1007\/978-3-642-60963-3_14"},{"issue":"9776","key":"10.1016\/j.ejphar.2018.08.007_bib144","doi-asserted-by":"crossref","first-page":"1506","DOI":"10.1016\/S0140-6736(11)60358-9","article-title":"Injectable extended-release naltrexone for opioid dependence: a double-blind, placebo-controlled, multicentre randomised trial","volume":"377","author":"Krupitsky","year":"2011","journal-title":"Lancet"},{"issue":"8","key":"10.1016\/j.ejphar.2018.08.007_bib145","doi-asserted-by":"crossref","first-page":"1793","DOI":"10.1038\/sj.npp.1300994","article-title":"Potentiation of low dose ketamine effects by naltrexone: potential implications for the pharmacotherapy of alcoholism","volume":"31","author":"Krystal","year":"2006","journal-title":"Neuropsychopharmacology"},{"issue":"6","key":"10.1016\/j.ejphar.2018.08.007_bib146","article-title":"FDA speeds smoking cessation drug review","volume":"295","author":"Kuehn","year":"2006","journal-title":"Jama"},{"issue":"1","key":"10.1016\/j.ejphar.2018.08.007_bib147","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1186\/1477-7517-6-4","article-title":"Opioid substitution treatment with sublingual buprenorphine in Manipur and Nagaland in Northeast India: what has been established needs to be continued and expanded","volume":"6","author":"Kumar","year":"2009","journal-title":"Harm Reduct. J."},{"issue":"1","key":"10.1016\/j.ejphar.2018.08.007_bib148","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1016\/j.drugalcdep.2010.03.021","article-title":"Retention in naltrexone implant treatment for opioid dependence","volume":"111","author":"Kun\u00f8e","year":"2010","journal-title":"Drug Alcohol Depend."},{"issue":"8","key":"10.1016\/j.ejphar.2018.08.007_bib149","doi-asserted-by":"crossref","first-page":"965","DOI":"10.1016\/S0028-3908(01)00140-X","article-title":"Gabapentin is not a GABAB receptor agonist","volume":"41","author":"Lanneau","year":"2001","journal-title":"Neuropharmacology"},{"issue":"2","key":"10.1016\/j.ejphar.2018.08.007_bib150","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1111\/dar.12095","article-title":"A systematic review and meta\u2010analysis of naltrexone implants for the treatment of opioid dependence","volume":"33","author":"Larney","year":"2014","journal-title":"Drug Alcohol Rev."},{"issue":"1","key":"10.1016\/j.ejphar.2018.08.007_bib151","first-page":"33","article-title":"Effectiveness and safety of baclofen in the treatment of alcohol dependent patients","volume":"9","author":"Leggio","year":"2010","journal-title":"CNS Neurol. Disord.-Drug Targets (Former. Curr. Drug Targets-CNS Neurol. Disord.)"},{"issue":"17","key":"10.1016\/j.ejphar.2018.08.007_bib152","doi-asserted-by":"crossref","first-page":"1580","DOI":"10.1056\/NEJMp1208498","article-title":"Why doctors prescribe opioids to known opioid abusers","volume":"367","author":"Lembke","year":"2012","journal-title":"New Engl. J. Med."},{"key":"10.1016\/j.ejphar.2018.08.007_bib153","article-title":"Gamma\u2010hydroxybutyrate (GHB) for treatment of alcohol withdrawal and prevention of relapses","author":"Leone","year":"2010","journal-title":"Cochrane Libr."},{"issue":"8","key":"10.1016\/j.ejphar.2018.08.007_bib154","doi-asserted-by":"crossref","first-page":"897","DOI":"10.1177\/1060028015585849","article-title":"The role of gabapentin in the management of alcohol withdrawal and dependence","volume":"49","author":"Leung","year":"2015","journal-title":"Ann. Pharmacother."},{"issue":"1 5","key":"10.1016\/j.ejphar.2018.08.007_bib155","doi-asserted-by":"crossref","first-page":"2263","DOI":"10.1517\/14656566.2014.955469","article-title":"Buprenorphine in the treatment of opioid addiction: opportunities, challenges and strategies","volume":"15","author":"Li","year":"2014","journal-title":"Expert Opin. Pharmacother."},{"issue":"7","key":"10.1016\/j.ejphar.2018.08.007_bib156","doi-asserted-by":"crossref","first-page":"899","DOI":"10.1177\/0269881112444324","article-title":"BAP updated guidelines: evidence-based guidelines for the pharmacological management of substance abuse, harmful use, addiction and comorbidity: recommendations from BAP","volume":"26","author":"Lingford-Hughes","year":"2012","journal-title":"J. Psychopharmacol."},{"issue":"S1","key":"10.1016\/j.ejphar.2018.08.007_bib157","doi-asserted-by":"crossref","DOI":"10.1080\/10550490490440799","article-title":"Implementing buprenorphine treatment in community settings in Australia: experiences from the Buprenorphine Implementation Trial","volume":"13","author":"Lintzeris","year":"2004","journal-title":"Am. J. Addict."},{"issue":"4","key":"10.1016\/j.ejphar.2018.08.007_bib158","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1097\/ADM.0b013e31829623f4","article-title":"A double-blind, placebo-controlled trial assessing the efficacy of varenicline tartrate for alcohol dependence","volume":"7","author":"Litten","year":"2013","journal-title":"J. Addict. Med."},{"issue":"2","key":"10.1016\/j.ejphar.2018.08.007_bib159","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1080\/08897077.2015.1133472","article-title":"Potential medications for the treatment of alcohol use disorder: an evaluation of clinical efficacy and safety","volume":"37","author":"Litten","year":"2016","journal-title":"Subst. Abus."},{"issue":"9","key":"10.1016\/j.ejphar.2018.08.007_bib160","doi-asserted-by":"crossref","first-page":"1179","DOI":"10.1111\/j.1360-0443.1995.tb01088.x","article-title":"Acamprosate in alcohol dependence: how does it work?","volume":"90","author":"Littleton","year":"1995","journal-title":"Addiction"},{"issue":"6","key":"10.1016\/j.ejphar.2018.08.007_bib161","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1111\/j.1755-5949.2010.00194.x","article-title":"Naltrexone depot formulations for opioid and alcohol dependence: a systematic review","volume":"17","author":"Lobmaier","year":"2011","journal-title":"CNS Neurosci. Ther."},{"issue":"1","key":"10.1016\/j.ejphar.2018.08.007_bib162","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1016\/j.drugalcdep.2013.05.010","article-title":"Efficacy of extended-release tramadol for treatment of prescription opioid withdrawal: a two-phase randomized controlled trial","volume":"133","author":"Lofwall","year":"2013","journal-title":"Drug Alcohol Depend."},{"issue":"22","key":"10.1016\/j.ejphar.2018.08.007_bib163","doi-asserted-by":"crossref","first-page":"2267","DOI":"10.1001\/jama.2017.4760","article-title":"More treatments on deck for alcohol use disorder","volume":"317","author":"Lyon","year":"2017","journal-title":"Jama"},{"issue":"2","key":"10.1016\/j.ejphar.2018.08.007_bib164","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1111\/j.1360-0443.2012.04054.x","article-title":"Meta\u2010analysis of naltrexone and acamprosate for treating alcohol use disorders: when are these medications most helpful?","volume":"108","author":"Maisel","year":"2013","journal-title":"Addiction"},{"key":"10.1016\/j.ejphar.2018.08.007_bib165","article-title":"Opioid epidemic in the United States","volume":"15","author":"Manchikanti","year":"2012","journal-title":"Pain Physician"},{"key":"10.1016\/j.ejphar.2018.08.007_bib166","doi-asserted-by":"crossref","unstructured":"Maneuf, Y. P., Luo, Z. D., Lee, K., 2006, October. \u03b12\u03b4 and the mechanism of action of gabapentin in the treatment of pain. In: Seminars in Cell & Developmental Biology. Academic Press, vol. 17(5), pp. 565-570). \u3008https:\/\/doi.org\/10.1016\/j.semcdb.2006.09.003\u3009.","DOI":"10.1016\/j.semcdb.2006.09.003"},{"issue":"8","key":"10.1016\/j.ejphar.2018.08.007_bib167","doi-asserted-by":"crossref","first-page":"706","DOI":"10.1016\/j.biopsych.2012.10.020","article-title":"Extending the treatment options in alcohol dependence: a randomized controlled study of as-needed nalmefene","volume":"73","author":"Mann","year":"2013","journal-title":"Biol. Psychiatry"},{"issue":"12","key":"10.1016\/j.ejphar.2018.08.007_bib168","doi-asserted-by":"crossref","first-page":"1941","DOI":"10.1016\/j.euroneuro.2016.10.008","article-title":"Nalmefene for the management of alcohol dependence: review on its pharmacology, mechanism of action and meta-analysis on its clinical efficacy","volume":"26","author":"Mann","year":"2016","journal-title":"Eur. Neuropsychopharmacol."},{"key":"10.1016\/j.ejphar.2018.08.007_bib169","doi-asserted-by":"crossref","first-page":"765","DOI":"10.7326\/0003-4819-85-6-765","article-title":"Naloxone","volume":"85","author":"Martin","year":"1976","journal-title":"Ann. Intern. Med."},{"issue":"6","key":"10.1016\/j.ejphar.2018.08.007_bib170","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1097\/JCP.0000000000000228","article-title":"Low-dose topiramate in alcohol dependence: a single-blind, placebo-controlled study","volume":"34","author":"Martinotti","year":"2014","journal-title":"J. Clin. Psychopharmacol."},{"issue":"7","key":"10.1016\/j.ejphar.2018.08.007_bib171","doi-asserted-by":"crossref","first-page":"662","DOI":"10.1021\/acsmedchemlett.6b00176","article-title":"Phenotypic assessment and the discovery of topiramate","volume":"7","author":"Maryanoff","year":"2016","journal-title":"ACS Med. Chem. Lett."},{"issue":"8","key":"10.1016\/j.ejphar.2018.08.007_bib172","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1001\/archpsyc.56.8.719","article-title":"A double-blind, placebo-controlled study of oral nalmefene for alcohol dependence","volume":"56","author":"Mason","year":"1999","journal-title":"Arch. General. Psychiatry"},{"issue":"1","key":"10.1016\/j.ejphar.2018.08.007_bib173","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1001\/jamainternmed.2013.11950","article-title":"Gabapentin treatment for alcohol dependence: a randomized clinical trial","volume":"174","author":"Mason","year":"2014","journal-title":"JAMA Intern. Med."},{"issue":"1","key":"10.1016\/j.ejphar.2018.08.007_bib174","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1080\/13543784.2018.1417383","article-title":"Gabapentin for the treatment of alcohol use disorder","volume":"27","author":"Mason","year":"2018","journal-title":"Expert Opin. Investig. Drugs Expert Opin. Investig. Drugs"},{"issue":"2","key":"10.1016\/j.ejphar.2018.08.007_bib175","doi-asserted-by":"crossref","DOI":"10.1002\/14651858.CD002207.pub3","article-title":"Buprenorphine maintenance versus placebo or methadone maintenance for opioid dependence","volume":"2","author":"Mattick","year":"2008","journal-title":"Cochrane Database Syst. Rev."},{"key":"10.1016\/j.ejphar.2018.08.007_bib176","first-page":"587","article-title":"Utilizing buprenorphine\u2013naloxone to treat illicit and prescription-opioid dependence","volume":"10","author":"Mauger","year":"2014","journal-title":"Neuropsychiatr. Dis. Treat."},{"issue":"2","key":"10.1016\/j.ejphar.2018.08.007_bib177","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1176\/appi.ajp.160.2.255","article-title":"Topiramate in the treatment of binge eating disorder associated with obesity: a randomized, placebo-controlled trial","volume":"160","author":"McElroy","year":"2003","journal-title":"Am. J. Psychiatry"},{"issue":"2","key":"10.1016\/j.ejphar.2018.08.007_bib178","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1016\/j.biopsych.2009.01.029","article-title":"Varenicline reduces alcohol self-administration in heavy-drinking smokers","volume":"66","author":"McKee","year":"2009","journal-title":"Biol. Psychiatry"},{"issue":"4","key":"10.1016\/j.ejphar.2018.08.007_bib179","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1111\/j.1525-1497.2005.04028.x","article-title":"Methadone medical maintenance in primary care","volume":"20","author":"Merrill","year":"2005","journal-title":"J. General. Intern. Med."},{"key":"10.1016\/j.ejphar.2018.08.007_bib180","article-title":"Human immunodeficiency virus seroconversion among intravenous drug users in-and out-of-treatment: an 18-month prospective follow-up","volume":"6","author":"Metzger","year":"1993","journal-title":"J. Acquir. Immune Defic. Syndr."},{"issue":"3","key":"10.1016\/j.ejphar.2018.08.007_bib181","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1007\/s00213-012-2717-x","article-title":"Varenicline decreases alcohol consumption in heavy-drinking smokers","volume":"223","author":"Mitchell","year":"2012","journal-title":"Psychopharmacology"},{"issue":"8","key":"10.1016\/j.ejphar.2018.08.007_bib182","first-page":"1386","article-title":"Naltrexone's effect on cue\u2010elicited craving among alcoholics in treatment","volume":"23","author":"Monti","year":"1999","journal-title":"Alcohol.: Clin. Exp. Res."},{"issue":"11","key":"10.1016\/j.ejphar.2018.08.007_bib183","doi-asserted-by":"crossref","first-page":"1634","DOI":"10.1111\/j.1530-0277.2001.tb02170.x","article-title":"Naltrexone and cue exposure with coping and communication skills training for alcoholics: treatment process and 1\u2010year outcomes","volume":"25","author":"Monti","year":"2001","journal-title":"Alcohol.: Clin. Exp. Res."},{"issue":"16","key":"10.1016\/j.ejphar.2018.08.007_bib184","doi-asserted-by":"crossref","first-page":"3845","DOI":"10.1111\/bph.12741","article-title":"The \u03b13\u03b24* nicotinic ACh receptor subtype mediates physical dependence to morphine: mouse and human studies","volume":"171","author":"Muldoon","year":"2014","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.ejphar.2018.08.007_bib185","series-title":"The American Disease: Origins of Narcotic Control","author":"Musto","year":"1987"},{"issue":"9","key":"10.1016\/j.ejphar.2018.08.007_bib186","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1007\/s40262-014-0155-0","article-title":"A population pharmacokinetic and pharmacodynamic modelling approach to support the clinical development of RBP-6000, a new, subcutaneously injectable, long-acting, sustained-release formulation of buprenorphine, for the treatment of opioid dependence","volume":"53","author":"Nasser","year":"2014","journal-title":"Clin. Pharmacokinet."},{"issue":"5","key":"10.1016\/j.ejphar.2018.08.007_bib187","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1097\/00000542-197605000-00008","article-title":"Pharmacokinetics of naloxone in rats and in man: basis for its potency and short duration of action","volume":"44","author":"Ngai","year":"1976","journal-title":"Anesthesiology"},{"key":"10.1016\/j.ejphar.2018.08.007_bib188","unstructured":"NIDA, 2016, November 1. Effective Treatments for Opioid Addiction. Retrieved from \u3008https:\/\/www.drugabuse.gov\/effective-treatments-opioid-addiction-0\u3009 on 2018, July 5."},{"issue":"2","key":"10.1016\/j.ejphar.2018.08.007_bib189","doi-asserted-by":"crossref","first-page":"606","DOI":"10.1016\/S0022-3565(25)22252-2","article-title":"Natural killer cell activity and lymphocyte subsets in parenteral heroin abusers and long-term methadone maintenance patients","volume":"250","author":"Novick","year":"1989","journal-title":"J. Pharmacol. Exp. Ther."},{"issue":"1","key":"10.1016\/j.ejphar.2018.08.007_bib190","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1001\/archinte.1990.00390130099014","article-title":"Absence of antibody to human immunodeficiency virus in long-term, socially rehabilitated methadone maintenance patients","volume":"150","author":"Novick","year":"1990","journal-title":"Arch. Intern. Med."},{"issue":"3","key":"10.1016\/j.ejphar.2018.08.007_bib191","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1016\/0376-8716(93)90110-C","article-title":"The medical status of methadone maintenance patients in treatment for 11\u201318 years","volume":"33","author":"Novick","year":"1993","journal-title":"Drug Alcohol Depend."},{"issue":"2\u20133","key":"10.1016\/j.ejphar.2018.08.007_bib192","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1080\/10550887.2015.1059225","article-title":"Methadone medical maintenance: an early 21st-century perspective","volume":"34","author":"Novick","year":"2015","journal-title":"J. Addict. Dis."},{"issue":"6","key":"10.1016\/j.ejphar.2018.08.007_bib193","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1159\/000452348","article-title":"Lifetime cocaine and opiate use and chronic kidney disease","volume":"44","author":"Novick","year":"2016","journal-title":"Am. J. Nephrol."},{"issue":"1","key":"10.1016\/j.ejphar.2018.08.007_bib194","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1177\/0269881113504017","article-title":"The role of the opioid system in alcohol dependence","volume":"28","author":"Nutt","year":"2014","journal-title":"J. Psychopharmacol."},{"issue":"8","key":"10.1016\/j.ejphar.2018.08.007_bib195","first-page":"421","article-title":"In vitro studies of the effect of methadone on natural killer cell activity","volume":"26","author":"Ochshorn","year":"1990","journal-title":"Isr. J. Med. Sci."},{"issue":"1","key":"10.1016\/j.ejphar.2018.08.007_bib196","doi-asserted-by":"crossref","first-page":"40","DOI":"10.7326\/0003-4819-133-1-200007040-00008","article-title":"Pharmacologic treatment of heroin-dependent patients","volume":"133","author":"O'Connor","year":"2000","journal-title":"Ann. Intern. Med."},{"issue":"11","key":"10.1016\/j.ejphar.2018.08.007_bib197","doi-asserted-by":"crossref","first-page":"881","DOI":"10.1001\/archpsyc.1992.01820110045007","article-title":"Naltrexone and coping skills therapy for alcohol dependence: a controlled study","volume":"49","author":"O'Malley","year":"1992","journal-title":"Arch. Gen. Psychiatry"},{"issue":"2","key":"10.1016\/j.ejphar.2018.08.007_bib198","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1016\/j.physbeh.2004.02.008","article-title":"Opioids and alcoholism","volume":"81","author":"Oswald","year":"2004","journal-title":"Physiol. Behav."},{"key":"10.1016\/j.ejphar.2018.08.007_bib199","first-page":"2","article-title":"Anticonvulsants for alcohol dependence","author":"Pani","year":"2010","journal-title":"Cochrane Database Syst. Rev."},{"issue":"1","key":"10.1016\/j.ejphar.2018.08.007_bib200","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1016\/j.drugalcdep.2009.07.013","article-title":"Long-term outcomes of office-based buprenorphine\/naloxone maintenance therapy","volume":"106","author":"Parran","year":"2010","journal-title":"Drug Alcohol Depend."},{"issue":"1","key":"10.1016\/j.ejphar.2018.08.007_bib201","first-page":"10","article-title":"Cdc grand rounds: prescription drug overdose-a us epidemic","volume":"61","author":"Paulozzi","year":"2012","journal-title":"Morb. Mortal. Wkly."},{"issue":"4","key":"10.1016\/j.ejphar.2018.08.007_bib202","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1080\/03007995.2017.1419171","article-title":"Abuse-deterrent opioids: an update on current approaches and considerations","volume":"34","author":"Pergolizzi","year":"2018","journal-title":"Curr. Med. Res. Opin."},{"key":"10.1016\/j.ejphar.2018.08.007_bib203","unstructured":"Pescor, M.J., 1943. A Statistical Analysis of the Clinical Records of Hospitalized Drugs Addicts, supplement No. 143. Public Health Reports, US Government Printing Office."},{"issue":"6","key":"10.1016\/j.ejphar.2018.08.007_bib204","doi-asserted-by":"crossref","first-page":"S3","DOI":"10.1097\/01.jcp.0000248602.68607.81","article-title":"A rational approach to the pharmacotherapy of alcohol dependence","volume":"26","author":"Petrakis","year":"2006","journal-title":"J. Clin. Psychopharmacol."},{"issue":"6","key":"10.1016\/j.ejphar.2018.08.007_bib205","doi-asserted-by":"crossref","first-page":"823","DOI":"10.1046\/j.1360-0443.2001.9668234.x","article-title":"Examining the limits of the buprenorphine interdosing interval: daily, every\u2010third\u2010day and every\u2010fifth\u2010day dosing regimens","volume":"96","author":"Petry","year":"2001","journal-title":"Addiction"},{"issue":"1","key":"10.1016\/j.ejphar.2018.08.007_bib206","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/j.neuropharm.2004.03.004","article-title":"Biphasic effect of acamprosate on NMDA but not on GABAA receptors in spontaneous rhythmic activity from the isolated neonatal rat respiratory network","volume":"47","author":"Pierrefiche","year":"2004","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.ejphar.2018.08.007_bib207","unstructured":"Pitk\u00e4nen, A., Buckmaster, P., Galanopoulou, A.S.,\u00a0Mosh\u00e9, S.L. (Eds.), 2017. Models of Seizures and Epilepsy. Academic Press."},{"issue":"11","key":"10.1016\/j.ejphar.2018.08.007_bib208","doi-asserted-by":"crossref","first-page":"1255","DOI":"10.1007\/s40265-015-0423-9","article-title":"Acamprosate: a review of its use in alcohol dependence","volume":"75","author":"Plosker","year":"2015","journal-title":"Drugs"},{"key":"10.1016\/j.ejphar.2018.08.007_bib209","first-page":"143","article-title":"Management of opioid addiction with buprenorphine: French history and current management","volume":"7","author":"Polom\u00e9ni","year":"2014","journal-title":"Int. J. Gen. Med."},{"issue":"1","key":"10.1016\/j.ejphar.2018.08.007_bib210","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/S0022-3565(25)21130-2","article-title":"Altered methadone pharmacokinetics in methadone-maintained pregnant women","volume":"233","author":"Pond","year":"1985","journal-title":"J. Pharmacol. Exp. Ther."},{"issue":"3","key":"10.1016\/j.ejphar.2018.08.007_bib211","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1007\/s00406-017-0801-2","article-title":"Psychiatric comorbidity in alcohol use disorders: results from the German S3 guidelines","volume":"268","author":"Preuss","year":"2018","journal-title":"Eur. Arch. Psychiatry Clin. Neurosci."},{"issue":"3","key":"10.1016\/j.ejphar.2018.08.007_bib212","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1016\/0741-8329(87)90038-3","article-title":"Morphine and diprenorphine together potentiate intake of alcoholic beverages","volume":"4","author":"Reid","year":"1987","journal-title":"Alcohol"},{"issue":"4","key":"10.1016\/j.ejphar.2018.08.007_bib213","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1016\/0741-8329(91)90305-G","article-title":"Tests of opioid deficiency hypotheses of alcoholism","volume":"8","author":"Reid","year":"1991","journal-title":"Alcohol"},{"key":"10.1016\/j.ejphar.2018.08.007_bib214","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1176\/appi.ajp.2017.1750101","article-title":"The American psychiatric association practice guideline for the pharmacological treatment of patients with alcohol use disorder","volume":"175","author":"Reus","year":"2018","journal-title":"Am. J. Psychiatry"},{"key":"10.1016\/j.ejphar.2018.08.007_bib215","doi-asserted-by":"crossref","first-page":"1459","DOI":"10.1517\/13543784.2015.1086746","article-title":"Therapies in early development for the treatment of opiate addiction","volume":"24","author":"Rodr\u00edguez-Arias","year":"2015","journal-title":"Expert Opin. Investig. Drugs"},{"key":"10.1016\/j.ejphar.2018.08.007_bib216","article-title":"Opioid antagonists for alcohol dependence","author":"R\u00f6sner","year":"2010","journal-title":"Cochrane Libr."},{"key":"10.1016\/j.ejphar.2018.08.007_bib217","article-title":"Acamprosate for alcohol dependence","author":"R\u00f6sner","year":"2010","journal-title":"Cochrane Libr."},{"issue":"2","key":"10.1016\/j.ejphar.2018.08.007_bib218","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/0376-8716(78)90022-4","article-title":"Human spinal fluid methadone levels","volume":"3","author":"Rubenstein","year":"1978","journal-title":"Drug Alcohol Depend."},{"issue":"1","key":"10.1016\/j.ejphar.2018.08.007_bib219","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1055\/s-2004-815473","article-title":"Effects of topiramate in the treatment of alcohol dependence","volume":"37","author":"Rubio","year":"2004","journal-title":"Pharmacopsychiatry"},{"key":"10.1016\/j.ejphar.2018.08.007_bib220","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1007\/s13181-015-0517-5","article-title":"Pharmacotherapy of opioid addiction: \u201cputting a real face on a false demon\u201d","volume":"12","author":"Salsitz","year":"2016","journal-title":"J. Med. Toxicol."},{"issue":"4","key":"10.1016\/j.ejphar.2018.08.007_bib221","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1037\/a0033724","article-title":"Randomized, placebo-controlled pilot trial of gabapentin during an outpatient, buprenorphine-assisted detoxification procedure","volume":"21","author":"Sanders","year":"2013","journal-title":"Exp. Clin. Psychopharmacol."},{"issue":"18","key":"10.1016\/j.ejphar.2018.08.007_bib222","doi-asserted-by":"crossref","first-page":"3799","DOI":"10.1007\/s00213-014-3518-1","article-title":"Varenicline effects on drinking, craving and neural reward processing among non-treatment-seeking alcohol-dependent individuals","volume":"231","author":"Schacht","year":"2014","journal-title":"Psychopharmacology"},{"issue":"4","key":"10.1016\/j.ejphar.2018.08.007_bib223","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1016\/j.jsat.2012.03.008","article-title":"Retention on buprenorphine treatment reduces emergency department utilization, but not hospitalization, among treatment-seeking patients with opioid dependence","volume":"43","author":"Schwarz","year":"2012","journal-title":"J. Subst. Abus. Treat."},{"key":"10.1016\/j.ejphar.2018.08.007_bib224","series-title":"The White Poppy: A History of Opium","author":"Scott","year":"1969"},{"issue":"4","key":"10.1016\/j.ejphar.2018.08.007_bib225","doi-asserted-by":"crossref","first-page":"879","DOI":"10.1111\/j.1530-0277.1994.tb00054.x","article-title":"Clinical efficacy of the 5\u2010HT3 antagonist ondansetron in alcohol abuse and dependence","volume":"18","author":"Sellers","year":"1994","journal-title":"Alcohol.: Clin. Exp. Res."},{"issue":"s1","key":"10.1016\/j.ejphar.2018.08.007_bib226","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1111\/j.1528-1157.2000.tb02163.x","article-title":"An overview of the preclinical aspects of topiramate: pharmacology, pharmacokinetics, and mechanism of action","volume":"41","author":"Shank","year":"2000","journal-title":"Epilepsia"},{"issue":"2","key":"10.1016\/j.ejphar.2018.08.007_bib227","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1517\/14656566.2014.863278","article-title":"Sodium oxybate in the treatment of alcohol dependence: from the alcohol withdrawal syndrome to the alcohol relapse prevention","volume":"15","author":"Skala","year":"2014","journal-title":"Expert Opin. Pharmacother."},{"issue":"8","key":"10.1016\/j.ejphar.2018.08.007_bib228","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1007\/s40263-013-0072-z","article-title":"Buprenorphine use in pregnant opioid users: a critical review","volume":"27","author":"Soyka","year":"2013","journal-title":"CNS Drugs"},{"issue":"4","key":"10.1016\/j.ejphar.2018.08.007_bib229","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1517\/14656566.2016.1146689","article-title":"Nalmefene for the treatment of alcohol use disorders: recent data and clinical potential","volume":"17","author":"Soyka","year":"2016","journal-title":"Expert Opin. Pharmacother."},{"issue":"12","key":"10.1016\/j.ejphar.2018.08.007_bib230","doi-asserted-by":"crossref","first-page":"1187","DOI":"10.1080\/14656566.2017.1349098","article-title":"Pharmacotherapy of alcoholism\u2013an update on approved and off-label medications","volume":"18","author":"Soyka","year":"2017","journal-title":"Expert Opin. Pharmacother."},{"issue":"2","key":"10.1016\/j.ejphar.2018.08.007_bib231","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1016\/S0165-6147(97)89800-8","article-title":"Anti-craving compounds for ethanol: new pharmacological tools to study addictive processes","volume":"18","author":"Spanagel","year":"1997","journal-title":"Trends Pharmacol. Sci."},{"issue":"30","key":"10.1016\/j.ejphar.2018.08.007_bib232","doi-asserted-by":"crossref","first-page":"12518","DOI":"10.1073\/pnas.0705368104","article-title":"Varenicline, an \u03b14\u03b22 nicotinic acetylcholine receptor partial agonist, selectively decreases ethanol consumption and seeking","volume":"104","author":"Steensland","year":"2007","journal-title":"Proc. Natl. Acad. Sci. USA"},{"issue":"3","key":"10.1016\/j.ejphar.2018.08.007_bib233","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1007\/s002130000637","article-title":"Effects of buprenorphine\/naloxone in opioid-dependent humans","volume":"154","author":"Stoller","year":"2001","journal-title":"Psychopharmacology"},{"issue":"3","key":"10.1016\/j.ejphar.2018.08.007_bib234","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1038\/clpt.2010.352","article-title":"Induction of opioid\u2010dependent individuals onto Buprenorphine and Buprenorphine\/naloxone soluble\u2010films","volume":"89","author":"Strain","year":"2011","journal-title":"Clin. Pharmacol. Ther."},{"issue":"3","key":"10.1016\/j.ejphar.2018.08.007_bib235","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1097\/01.jcp.0000222512.25649.08","article-title":"The status of disulfiram: a half of a century later","volume":"26","author":"Suh","year":"2006","journal-title":"J. Clin. Psychopharmacol."},{"issue":"3","key":"10.1016\/j.ejphar.2018.08.007_bib236","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1016\/S0920-1211(97)00084-3","article-title":"A summary of mechanistic hypotheses of gabapentin pharmacology","volume":"29","author":"Taylor","year":"1998","journal-title":"Epilepsy Res."},{"issue":"2","key":"10.1016\/j.ejphar.2018.08.007_bib237","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1016\/S0376-8716(01)00161-2","article-title":"Buprenorphine prescription by general practitioners in a French region","volume":"65","author":"Thirion","year":"2002","journal-title":"Drug Alcohol Depend."},{"issue":"2","key":"10.1016\/j.ejphar.2018.08.007_bib238","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1176\/appi.ps.201300256","article-title":"Medication-assisted treatment with buprenorphine: assessing the evidence","volume":"65","author":"Thomas","year":"2014","journal-title":"Psychiatr. Serv."},{"issue":"8\u20109","key":"10.1016\/j.ejphar.2018.08.007_bib239","doi-asserted-by":"crossref","first-page":"506","DOI":"10.1002\/j.1552-4604.1980.tb02543.x","article-title":"Methadone\u2014disulfiram interaction during methadone maintenance","volume":"20","author":"Tong","year":"1980","journal-title":"J. Clin. Pharmacol."},{"issue":"3","key":"10.1016\/j.ejphar.2018.08.007_bib240","doi-asserted-by":"crossref","first-page":"349","DOI":"10.7326\/0003-4819-94-3-349","article-title":"Phenytoin-induced methadone withdrawal","volume":"94","author":"Tong","year":"1981","journal-title":"Ann. Intern. Med."},{"issue":"4","key":"10.1016\/j.ejphar.2018.08.007_bib241","first-page":"53","article-title":"Opiate maintenance treatment in primary health care in Germany","volume":"12","author":"Ullmann","year":"2010","journal-title":"Heroin Addict. Relat. Clin. Probl."},{"issue":"2","key":"10.1016\/j.ejphar.2018.08.007_bib242","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1517\/14740338.6.2.125","article-title":"Naloxone treatment in opioid addiction: the risks and benefits","volume":"6","author":"van Dorp","year":"2007","journal-title":"Expert Opin. Drug Saf."},{"issue":"5","key":"10.1016\/j.ejphar.2018.08.007_bib243","first-page":"305","article-title":"The mechanism of alcohol intolerance produced by various therapeutic agents","volume":"58","author":"Vasiliou","year":"1986","journal-title":"Basic Clin. Pharmacol. Toxicol."},{"issue":"12","key":"10.1016\/j.ejphar.2018.08.007_bib244","doi-asserted-by":"crossref","first-page":"963","DOI":"10.1038\/nrn1539","article-title":"Drug addiction: the neurobiology of behaviour gone awry","volume":"5","author":"Volkow","year":"2004","journal-title":"Nat. Rev. Neurosci."},{"issue":"4","key":"10.1016\/j.ejphar.2018.08.007_bib245","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1176\/ajp.152.4.613","article-title":"Effect of naltrexone on alcohol\" high\" in alcoholics","volume":"152","author":"Volpicelli","year":"1995","journal-title":"Am. J. Psychiatry"},{"issue":"8","key":"10.1016\/j.ejphar.2018.08.007_bib246","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1001\/archpsyc.1997.01830200071010","article-title":"Naltrexone and alcohol dependence: role of subject compliance","volume":"54","author":"Volpicelli","year":"1997","journal-title":"Arch. Gen. Psychiatry"},{"issue":"3","key":"10.1016\/j.ejphar.2018.08.007_bib247","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1038\/sj.npp.1301438","article-title":"Pharmacological evidence for a motivational role of \u03ba-opioid systems in ethanol dependence","volume":"33","author":"Walker","year":"2008","journal-title":"Neuropsychopharmacology"},{"issue":"4","key":"10.1016\/j.ejphar.2018.08.007_bib248","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1016\/j.alcohol.2011.10.006","article-title":"Targeting dynorphin\/kappa opioid receptor systems to treat alcohol abuse and dependence","volume":"46","author":"Walker","year":"2012","journal-title":"Alcohol"},{"key":"10.1016\/j.ejphar.2018.08.007_bib249","doi-asserted-by":"crossref","first-page":"f174","DOI":"10.1136\/bmj.f174","article-title":"Opioid overdose rates and implementation of overdose education and nasal naloxone distribution in Massachusetts: interrupted time series analysis","volume":"346","author":"Walley","year":"2013","journal-title":"Bmj"},{"issue":"5","key":"10.1016\/j.ejphar.2018.08.007_bib250","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1038\/clpt.1994.71","article-title":"Clinical pharmacology of buprenorphine: ceiling effects at high doses","volume":"55","author":"Walsh","year":"1994","journal-title":"Clin. Pharmacol. Ther."},{"issue":"1","key":"10.1016\/j.ejphar.2018.08.007_bib251","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1016\/S0022-3565(25)10510-7","article-title":"Acute administration of buprenorphine in humans: partial agonist and blockade effects","volume":"274","author":"Walsh","year":"1995","journal-title":"J. Pharmacol. Exp. Ther."},{"issue":"1\u20132","key":"10.1016\/j.ejphar.2018.08.007_bib252","first-page":"5","article-title":"NIAAA: Advancing alcohol research for 40 years","volume":"33","author":"Warren","year":"2010","journal-title":"Alcohol Res. Health"},{"issue":"12","key":"10.1016\/j.ejphar.2018.08.007_bib253","doi-asserted-by":"crossref","first-page":"1238","DOI":"10.1001\/archgenpsychiatry.2011.121","article-title":"Adjunctive counseling during brief and extended buprenorphine-naloxone treatment for prescription opioid dependence: a 2-phase randomized controlled trial","volume":"68","author":"Weiss","year":"2011","journal-title":"Arch. Gen. Psychiatry"},{"issue":"3","key":"10.1016\/j.ejphar.2018.08.007_bib254","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1592\/phco.26.3.375","article-title":"Topiramate for migraine prevention","volume":"26","author":"Wenzel","year":"2006","journal-title":"Pharmacother.: J. Hum. Pharmacol. Drug Ther."},{"key":"10.1016\/j.ejphar.2018.08.007_bib255","series-title":"The WHO Guidelines for the Psychosocially Assisted Pharmacological Treatment of Opioid Dependence","author":"World Health Organization (WHO)","year":"2009"},{"key":"10.1016\/j.ejphar.2018.08.007_bib256","volume":"2014","author":"World Health Organization, & World Health Organization. Management of Substance Abuse Unit","year":"2014"},{"issue":"3","key":"10.1016\/j.ejphar.2018.08.007_bib257","doi-asserted-by":"crossref","first-page":"1136","DOI":"10.1124\/jpet.104.082560","article-title":"Pharmacokinetic-pharmacodynamic modeling of the antinociceptive effect of buprenorphine and fentanyl in rats: role of receptor equilibration kinetics","volume":"313","author":"Yassen","year":"2005","journal-title":"J. Pharmacol. Exp. Ther."},{"issue":"10","key":"10.1016\/j.ejphar.2018.08.007_bib258","doi-asserted-by":"crossref","first-page":"1078","DOI":"10.1002\/jcph.110","article-title":"The effects of alcohol on the pharmacokinetics and pharmacodynamics of the selective mu\u2010opioid receptor antagonist GSK1521498 in healthy subjects","volume":"53","author":"Ziauddeen","year":"2013","journal-title":"J. Clin. Pharmacol."}],"container-title":["European Journal of Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0014299918304515?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0014299918304515?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,7,6]],"date-time":"2025-07-06T07:22:52Z","timestamp":1751786572000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0014299918304515"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,10]]},"references-count":258,"alternative-id":["S0014299918304515"],"URL":"https:\/\/doi.org\/10.1016\/j.ejphar.2018.08.007","relation":{},"ISSN":["0014-2999"],"issn-type":[{"value":"0014-2999","type":"print"}],"subject":[],"published":{"date-parts":[[2018,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Pharmacological treatments for opiate and alcohol addiction: A historical perspective of the last 50 years","name":"articletitle","label":"Article Title"},{"value":"European Journal of Pharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejphar.2018.08.007","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}